首页 | 本学科首页   官方微博 | 高级检索  
检索        

醒脑静注射液对脑缺血再灌注损伤家兔血清白细胞介素8的影响
引用本文:王万铁,陈寿权,徐正档,王卫,李惠萍,黄唯佳,程俊彦,赵初环,方周溪,卢中秋.醒脑静注射液对脑缺血再灌注损伤家兔血清白细胞介素8的影响[J].中国组织工程研究与临床康复,2004,8(16):3210-3211.
作者姓名:王万铁  陈寿权  徐正档  王卫  李惠萍  黄唯佳  程俊彦  赵初环  方周溪  卢中秋
作者单位:1. 温州医学院病理生理教研室,浙江省温州市 325027
2. 温州医学院附属第一医院急诊科,浙江省温州市 325027
3. 温州医学院电镜室,浙江省温州市 325027
基金项目:浙江省中医药管理局资助项目(No.98037)~~
摘    要:背景目前有关醒脑静注射液(xingnaojing injection,XNJI)对脑缺血再灌注损伤(cerebralischemia-reperfusioninjury,CIRI)时血清白细胞介素8水平的影响,及其脑功能保护机制研究尚少.目的观察XNJI对CIRI家兔血清白细胞介素8水平的影响,并探讨其脑保护机制.设计完全随机设计,对照实验研究.地点与材料本研究的地点为温州医学院病理生理教研室.材料为选用28只日本大耳白兔,雌雄不拘,体质量2.2~3.0 kg,由温州医学院实验动物中心提供.干预28只家兔随机分为假手术对照组、缺血再灌注组和醒脑静注射液组,分别在缺血前、缺血30min、再灌注30min,60min,120min取静脉血,测定血清白细胞介素8浓度,实验结束取脑组织观察脑超微结构的变化.主要观察指标血清白细胞介素8浓度的动态变化;脑组织超微结构的改变.结果脑缺血再灌注期间,缺血再灌注组不同时点血清白细胞介素8水平明显高于醒脑静注射液组缺血30 min为(0.62±0.18)ng/L及(0.43±0 08)ng/L,P<0.05;再灌注30 nin,为(0.73±0.19)ng/L及(0.45±0.09)ng/L;再灌注60 min,为(0.87±0.29)ng/L及(0.47±0.06)ng/L;再灌注120min为(1.03±0.43)ng/L及(0.44±0.07)ng/L,再灌注各时点组均P<0.0.01),超微结构发生异常改变;醒脑静注射液组不同时点血清白细胞介素8浓度显著低于缺血再灌注组醒脑静注射液组缺血30min为(0.48±0.07)ng/L,P<0.05;再灌注30 min,(0.50±0.08)ng/L;再灌注60 min为(0.55±0.14)ng/L;再灌注120 min为(0.59±0.17)ng/L,再灌注各时点组P<0.01),其超微结构异常改变较缺血再灌注组明显减轻.结论XNJI能有效降低白细胞介素8的水平,这可能是它减轻CIRI的又一重要机制.

关 键 词:再灌注损伤  脑缺血  白细胞介素-8  药物疗法

Impact of xingnaojing injection on serous interleukin-8 in cerebral ischemia-reperfusion injury in rabbit
Abstract.Impact of xingnaojing injection on serous interleukin-8 in cerebral ischemia-reperfusion injury in rabbit[J].Journal of Clinical Rehabilitative Tissue Engineering Research,2004,8(16):3210-3211.
Authors:Abstract
Abstract:BACKGROUND: There were few researches on the impact and the protective mechanism on cerebral function of xingnaojing injection(XNJI) on serous interleukin-8(IL-8) in cerebral ischemia-reperfusion injury (CIRI).OBJECTIVE: To observe the impact of XNJI on the IL-8 in CIRI of rabbit and to discuss its cerebral protective mechanism.DESIGN: A completely randomized controlled study.SETTING and MATERIALS: Study was completed in the department of pathophysiology of Wenzhou Medical University. Materials were 28 Japanese rabbits in either gender with a body weight from 2.2 kg to 3.0 kg obtained from the experimental animal center of Wenzhou Medical University.INTERVENTIONS: Twenty-eight rabbits were randomly allocated into sham-operation group, CIRI group and XNJI group. Venous blood was drawn separately at before ischemia, 30 minutes after ischemia, 30 minutes after reperfusion, 60 minutes after reperfusion and 120 minutes after reperfusion for detecting the strength of serous IL-8 level. The brain tissue was taken after the experiment for observing the changes in cerebral ultrastructure.MAIN OUTCOME MEASURES: The dynamic changes of serous IL-8levels, the changes in the ultrastructure of brain tissue.RESULTS: During CIRI period, the serous IL-8 levels in CIRI group over time were significantly higher than that of XNJI groupthe levels at 30 minutes after ischemia were(0.62 +0. 18) ng/L and(0. 43 +0. 08) ng/L respectively, P <0.05; the levels at 30 minutes after reperfusion were(0.73 +0. 19) ng/L and (0.45 +0.09) ng/L respectively; the levels at 60 minutes after reperfusion were(0. 87 + 0.29) ng/L and(0.47 + 0.06) ng/L respectively; the level at 120minutes after reperfusion were(1.03 ±0.43) ng/L and(0. 44 +0. 07) ng/L respectively; P < 0.01 ]. There were abnormal changes in ultrastructure. The serous IL-8 strength over times in XNJI group significantly lower than that of CIRI groupthe strength at 30 minutes after ischemia in XNJI group was(0. 48 ±0.07) ng/L, P < 0.05; the strength at 30 minutes after reperfusionwas(0.50 ±0.08) ng/L; the strength at 60 minutes after reperfusion was(0.55 +0. 14) ng/L; the strength at 120 minutes after reperfusion was(0.59 ±0. 17) ng/L; P < 0.01] . The abnormal changes in ultrastrueture were significantly alleviated compared with CIRI group.CONCLUSION: XNJI could effectively decrease the IL-8 level, which might be another important mechanism in alleviating CIRI.
Keywords:
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号